Altay Therapeutics undisclosed transcription factor inhibitor

Altay Therapeutics is developing an early-stage small molecule program targeting an undisclosed transcription factor for the treatment of sarcomas and prostate cancer. The program utilizes Altay's proprietary drug discovery platform, which is designed to identify small molecule binding pockets within the intrinsically disordered domains of transcription factors—targets traditionally considered 'undruggable' due to their lack of defined structural pockets. By modulating these transcription factors, the therapy aims to disrupt disease-driving gene expression patterns. While the specific target remains undisclosed by the company, some literature associates the compound PCE-0034 with Altay's efforts in Ewing's sarcoma and prostate cancer.

Other names

Altay Therapeutics undisclosed transcription factor program